If you have been reading about angiotensin IV and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-01. Numbers and descriptions here follow the published literature rather than marketing material.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
| Property | Value | Notes |
|---|---|---|
| Typical analytical method | LC-MS and HPLC | Used for identity and purity assessment. |
| Purity specification | ≥95% or ≥98% in research grades | Actual purity depends on supplier and batch. |
| Stability in solution | Limited; prepare fresh | Aqueous and organic stocks may degrade over time. |
| Recommended storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles. |
| Regulatory status | Not approved for human use | Sold as a research chemical in some regions. |
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Temperature-responsive polymers or thermoresponsive polymers are polymers that exhibit drastic and discontinuous changes in their physical properties with temperature. The term is commonly used when the property concerned is solubility in a given solvent, but it may also be used when other properties are affected. Thermoresponsive polymers belong to the class of stimuli-responsive materials, in contrast to temperature-sensitive (for short, thermosensitive) materials, which change their properties continuously with environmental conditions. In a stricter sense, thermoresponsive polymers display a miscibility gap in their temperature-composition diagram. Depending on whether the miscibility gap is found at high or low temperatures, either an upper critical solution temperature (UCST) or a lower critical solution temperature (LCST) exists.
=== Mechanism === Legumain is a cysteine protease from the C13 family of the CD clan of proteases (MEROPS). It uses a catalytic triad of Cysteine-Histidine-Asparagine in its active site to perform covalent proteolysis of its substrate.
Balanced anesthesia, also known as multimodal anesthesia (also spelt: anaesthesia), is a technique used to induce and maintain anesthesia in patients undergoing surgery or certain medical procedures. This method employs a combination of anesthetic agents and other drugs – and techniques – to selectively target various aspects of the central nervous system, allowing for a tailored anesthetic experience based on the individual patient's needs and the specific requirements of the procedure. The specialist physician (in Canadian and American English: anesthesiologist; in Commonwealth and British English: anaesthetist) or veterinarian evaluates various patient factors prior to selecting an anesthetic approach. These factors include major organ function, general condition, and compensatory capacity (ability to function despite stressors). In balanced anesthesia, appropriate agents are used in combination, at carefully-calibrated levels. The concept of balanced anesthesia was first introduced by John Silas Lundy in 1926 and has since become the predominant method of anesthesia in modern medical practice.
=== Pharmacokinetics === Butizide is quickly absorbed from the gut with a bioavailability of 85%. It reaches highest blood plasma concentrations after 2.5 hours. Plasma protein binding is 60 to 80%. While the substance is metabolised in the liver, 30% are excreted in unchanged from with the urine. Elimination half-life is about four hours.
Sources: en.wikipedia.org
=== SARS-CoV-2 (COVID-19) === In the beginning of the COVID-19 pandemic, then-US President Donald Trump delivered a very dangerous message to the public on the use of disinfectants, which was immediately rejected and refuted by health professionals. In essence, and as mentioned above, virucides are usually toxic depending on concentrations, mixture, etc., and can be deadly not just to viruses, but also if inside a human or animal body or on surface of body. With regards to the COVID-19 pandemic, some of the mentioned agents are still under research about their microbicidal activity and effectivity against SARS-CoV-2, e.g., on surfaces, as mouth-washes, hand-washing, etc. A mixture of 62–71% ethanol, 0.5% hydrogen peroxide or 0.1% sodium hypochlorite is found to be able to deactivate the novel Coronavirus on surfaces within 1 minute. A 2020 systematic review on hydrogen peroxide (H2O2) mouth-washes concludes, that they don't have an effect on virucidal activity, recommending that "dental care protocols during the COVID-19 pandemic should be revised." Additional research with relation to the Coronavirus virucidal efficacy is on-going. Various information and overview of light-based strategies (UV-C and other types of light sources; see also Ultraviolet germicidal irradiation) to combat the COVID-19 pandemic are available.
The United States has had eight Olympic medals stripped for doping violations. In the case of swimmer Rick DeMont, the USOC recognized his gold-medal performance in the 1972 Summer Olympics in 2001, but only the IOC has the power to restore his medal, and it has as of 2017 refused to do so. DeMont originally won the gold medal in 4:00.26. Following the race, the IOC stripped him of his gold medal after his post-race urinalysis tested positive for traces of the banned substance ephedrine contained in his prescription asthma medication, Marax. The positive test following the 400 meter freestyle final also deprived him of a chance at multiple medals, as he was not permitted to swim in any other events at the 1972 Olympics, including the 1,500-meter freestyle for which he was the then-current world record-holder. Before the Olympics, DeMont had properly declared his asthma medications on his medical disclosure forms, but the USOC had not cleared them with the IOC's medical committee. In 2003, Wade Exum, the United States Olympic Committee's director of drug-control administration from 1991 to 2000, gave copies of documents to Sports Illustrated that revealed that some 100 American athletes failed drug tests from 1988 to 2000, arguing that they should have been prevented from competing in the Olympics but were nevertheless cleared to compete; those athletes included Carl Lewis, Joe DeLoach and Floyd Heard.
He added that "China's sovereignty, security, and development interests cannot be violated, and four red lines — the Taiwan question, democracy and human rights, development paths and systems, and development rights — cannot be challenged". Shortly after Xi arrived to the US on September 23, Treasury Secretary Bessent announced that the trade truce between the two countries, reached at the Busan Summit and was set to expire on November 10, would be extended until January 10, 2027. On September 24, Chinese defense ministry spokesperson Jiang Bin said that "it should be emphasized that the Taiwan question is the most important in China–US relations and maintaining peace and stability in the Taiwan Strait is the greatest common issue of the two countries and that "it is hoped that the US side will handle the Taiwan issue with extreme caution". Due to Trump's recent ban of several news outlets from the White House, most of Xi's state visit was not covered by the White House press pool. ABC World News Tonight placed the news of Xi's as the third item, with only photos and no video. CNN reported that the Chinese side had informally expressed its concerns to the United States that the boycott would affect the coverage of the visit. On September 24, the Trump administration returned the press credentials to the three media outlets, but still excluded CNN. The opening remarks of the summit meeting that day were not made public to the media as is customary, meaning the only publicly available video recording of the meeting was the segment broadcast by China Central Television.
== Controversy == Doctor's Data has proven controversial because of the four lawsuits that have been filed by people who say that the company victimized them by diagnosing them as having toxic metal poisoning based on their urinalysis tests, and then prescribing them chelation therapy. According to Patricia Callahan, the problem with these tests and the way they are interpreted is that, after administering a chelator to their patients, "Doctor's Data...compared those drug-provoked results to a reference range calculated for people who had never been given a chelation drug." In addition, they have faced considerable criticism from Stephen Barrett, who has described how provoked urine test reports are used to mislead patients. and has also written negatively about hair analysis in general, which he contends is "unscientific, economically wasteful, and probably illegal." Arthur Allen has also criticized the methodology of their urinalysis tests, saying that they "...present the results [from their urine analysis tests] in such a way that it almost guarantees a finding of "toxicity" for each child." In response to this criticism, Doctor's Data president Ted Lueken argued that "the technique can be valuable when used along with other tests and a doctor's knowledge of his patient." Doctor's Data later sued Barrett on June 18, 2010, accusing him of "...harm[ing] Doctor's Data by transmitting false, fraudulent and defamatory information about this company in a variety of ways" in his writings about the company.
== Erinacine C == Erinacine C has also been observed to activate the transcription factor Nrf2 and has been observed to play a role in neurogenesis and neuroplasticity. Stimulator of NGF synthesis in vitro((299.1 ± 59.6) pg/mL at 1.0 mmol/L)
Sources: en.wikipedia.org
==== Drug levels, androgen levels, and efficacy ==== The affinity of bicalutamide for the AR is approximately 30 to 100 times lower than that of DHT (IC50 ≈ 3.8 nM), the main endogenous ligand of the receptor in the prostate gland. However, sufficiently high relative concentrations of bicalutamide (1,000- to 10,000-fold excess) are able to completely prevent activation of the AR by androgens like DHT and testosterone and subsequent upregulation of the transcription of androgen-responsive genes and associated effects. At steady-state, relative to the normal adult male range for testosterone levels (300–1,000 ng/dL), circulating concentrations of bicalutamide at 50 mg/day are roughly 600 to 2,500 times higher and at 150 mg/day around 1,500 to 8,000 times higher than circulating testosterone levels, while bicalutamide concentrations, relative to the mean testosterone levels present in men who have been surgically castrated (15 ng/dL), are approximately 42,000 times higher than testosterone levels at 50 mg/day.
with sufficient accuracy for most practical purposes. In effect there is no need to define pKb separately from pKa, but it is done here as often only pKb values can be found in the older literature. For a hydrolyzed metal ion, Kb can also be defined as a stepwise dissociation constant
== Treatment == The major emphasis of the treatment of JIA is helping the child or young person regain normal levels of physical and social functioning by controlling inflammation and extra-articular symptoms. Clinical remission should be the primary target for all people. Prompt recognition and management is important as early initiation of medication therapy increases the likelihood of a response to first-line treatments and low disability. Consensus treatment guidelines exist for the treatment of JIA. Optimal management of JIA requires a multidisciplinary team working to address the needs of an individual child. Optimizing physical and social functioning is accomplished using non-pharmacological strategies such as physical therapies, pain management strategies, and social supports. Medications are used to control inflammation and reduce or prevent extra-articular symptoms.Non-steroidal anti-inflammatory drugs (NSAIDs) are used for symptomatic relief of joint pain in children with JIA. Disease-modifying antirheumatic drugs (DMARDs), which inhibit specific pathways in the inflammation pathways responsible for JIA, are a primary treatment. Lifelong DMARD treatment is often required, and drug-free remission is exceedingly rare. Oligoarticular JIA (which comprises 40-50% of all JIA cases) by definition involves 4 or fewer joints in the first 6 months of the disease. After 6 months, some cases become polyarticular (involving more than 4 joints). This polyarticular subtype is associated with a lower remission rate with medical therapy.
Allysine is involved in the production of elastin and collagen. Increased allysine concentration in tissues has been correlated to the presence of fibrosis. Allysine residues react with sodium 2-naphthol-6-sulfonate to produce a fluorescent bis-naphtol-allysine product. In another assay, allysine-containing proteins are reduced with sodium borohydride to give a peptide containing the 6-hydroxynorleucine (6-hydroxy-2-aminocaproic acid) residue, which (unlike allysine) is stable to proteolysis.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is commonly used. It provides molecular mass and purity information. Other methods may include HPLC with ultraviolet detection.
Dihexa is often described as an HGF mimetic that activates c-Met signaling. Some research also links it to angiotensin IV pathways. The precise targets and human relevance remain uncertain.
The powder is typically stored at -20 °C, desiccated and protected from light. Avoid repeated freeze-thaw cycles. Follow supplier instructions and institutional guidelines.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.